

A Retroelement Modifies Pre-mRNA Splicing

THE MURINE *Glr^b^{spa}* ALLELE IS A SPLICING SIGNAL POLYMORPHISM AMPLIFIED BY LONG INTERSPERSED NUCLEAR ELEMENT INSERTION*

Received for publication, April 27, 2012, and in revised form, July 9, 2012. Published, JBC Papers in Press, July 10, 2012, DOI 10.1074/jbc.M112.375691

Kristina Becker[‡], Marlen Braune[‡], Natalya Benderska[‡], Emanuele Buratti[§], Francisco Baralle[§], Carmen Villmann[‡], Stefan Stamm^{‡1}, Volker Eulenburg^{‡2}, and Cord-Michael Becker[‡]

From the [‡]Institut für Biochemie, Emil Fischer Zentrum, Universität Erlangen-Nürnberg, 91054 Erlangen, Germany and the

[§]International Center of Genetic Engineering and Biotechnology, 34149 Trieste, Italy

Background: The mouse mutant *spastic* carries a retrotransposon insertion in the *Glr^b* gene leading to missplicing.

Results: *Glr^b* missplicing in the *spastic* allele results from an exonic SNP amplified by retrotransposon insertion.

Conclusion: The consequences of retrotransposon insertions depend on the properties of the element and on its genomic environment.

Significance: SNPs without transcriptional relevance might contribute to disease phenotypes after additional gene alteration.

The glycine receptor-deficient mutant mouse *spastic* carries a full-length long interspersed nuclear element (LINE1) retrotransposon in intron 6 of the glycine receptor β subunit gene, *Glr^b^{spa}*. The mutation arose in the C57BL/6J strain and is associated with skipping of exon 6 or a combination of the exons 5 and 6, thus resulting in a translational frameshift within the coding regions of the GlyR β subunit. The effect of the *Glr^b^{spa}* LINE1 insertion on pre-mRNA splicing was studied using a minigene approach. Sequence comparison as well as motif prediction and mutational analysis revealed that in addition to the LINE1 insertion the inactivation of an exonic splicing enhancer (ESE) within exon 6 is required for skipping of exon 6. Reconstitution of the ESE by substitution of a single residue was sufficient to prevent exon skipping. In addition to the ESE, two regions within the 5' and 3' UTR of the LINE1 were shown to be critical determinants for exon skipping, indicating that LINE1 acts as efficient modifier of subtle endogenous splicing phenotypes. Thus, the *spastic* allele of the murine glycine receptor β subunit gene is a two-hit mutation, where the hypomorphic alteration in an ESE is amplified by the insertion of a LINE1 element in the adjacent intron. Conversely, the LINE1 effect on splicing may be modulated by individual polymorphisms, depending on the insertional environment within the host genome.

Glycine receptors (GlyRs)³ belong to the superfamily of Cys-loop containing ligand-gated ion channels and mediate fast

inhibitory neurotransmission preferentially in spinal cord and brainstem (1). GlyRs are a pentameric assembly of developmentally regulated proteins composed of two α 1 and three β subunits (2, 3). Mutations in GlyR genes are one of the major causes of the hereditary neuromotor disorder hyperekplexia (*STHE*, OMIM accession no. 149000) in humans and mice (4). In the GlyR mutant mouse *spastic* (*Glr^b^{spa}* mice), a full-length long interspersed nuclear element (LINE1) has been inserted in anti-sense orientation in intron 6 of the GlyR β subunit gene, *Glr^b* (5, 6). Although exons 5 and 6 of the *Glr^b* transcripts are constitutively spliced in wild-type mice, exon 6 or both exons 5 and 6, are skipped in homozygous *Glr^b^{spa}/*spa** mice (5, 6). This exon skipping results in a translational frameshift and, as a consequence, leads to a profound numerical reduction of functional GlyRs (6, 7).

LINE1 elements are the most abundant autonomous retrotransposons in mammalian genomes (8, 9). All full-length LINE1 elements share an identical structural organization, comprised of two ORF, ORF1, and ORF2 which are flanked by 5' and 3' UTRs, respectively. ORF1 encodes a RNA binding protein (pORF1, 40 kDa), and ORF2 encodes a protein exerting endonuclease as well as reverse transcriptase activities (pORF2, 150 kDa). Most of the full-length LINE1 elements present in mammalian genomes are rendered retrotransposition-incompetent through nonsense or frameshift mutations, 5' truncations, or internal rearrangements (10, 11). In humans and mice, LINE1-associated diseases are most frequently caused by insertions into either exons or gene regulatory sequences, resulting in gene dysfunction (9, 12). Moreover, homologous recombination of LINE1 at non-allelic chromosomal sites are thought to underlie genomic rearrangements reflected by deletions or insertions (13, 14). The high frequency of LINE1 elements within intronic sequences is contrasted by a relatively low number of known pathological phenotypes. In some human genetic disorders (15, 16) and in the mutant mouse *spastic* (5, 6), however, intronic insertions of LINE1 elements are associated with aberrant splicing. The mechanism resulting in missplicing is not yet fully understood. LINE1-dependent interference has been attributed to a variety of mechanisms, including disrupt-

* This work was supported by Deutsche Forschungsgemeinschaft (BE 1138/5-3), the Bundesministerium für Forschung und Bildung/Deutsche Projektkooperation (BMBF/DIP G3.2), the NIH (GM083187), and Fonds der Chemischen Industrie (160-43).

¹ Present address: Dept. of Biochemistry, University of Kentucky, Lexington, KY 40536-0298.

² To whom correspondence should be addressed: Institut für Biochemie, Emil Fischer Zentrum, Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany. Tel.: 49-9131-852-6206; Fax: 49-9131-852-2485; E-mail: Volker.eulenburg@biochem.uni-erlangen.de.

³ The abbreviations used are: GlyR, glycine receptor; LINE1, long interspersed nuclear element 1; ESE, exonic splicing enhancer; SRSF1, SR protein splicing factor 1.

This is an Open Access article under the [CC BY](#) license.

Molecular Analysis of *Glr*b Missplicing in *Glr*b^{spa} Mice

tion of consensus splice sites or RNA regulatory motifs such as intronic splicing enhancers or silencers (8). Moreover, bioinformatic analysis indicated that intronic LINE1 insertion in sense orientation are underrepresented compared with antisense insertions, suggesting an underlying negative selection (12, 17). In this study, we used the *Glr*b^{spa} gene, and recombinant variations thereof, as a model system for studying the molecular mechanism by which a full-length intronic LINE1 insertion affects pre-mRNA splicing.

To elucidate the pathomechanism by which the LINE1 affects splicing in *Glr*b^{spa} mice, *in vivo* splicing assays were conducted in human embryonic kidney (HEK293) cells using minigenes encompassing *Glr*b exons 4–7 with intervening partial or full-length intronic sequences. Because the *Glr*b^{spa} allele was first discovered in a B6C3Fe hybrid background, we used DNA from the parental inbred lines C57BL/6J *Glr*b^{+/+} and C3H/HeJ *Glr*b^{+/+} and from the inbred *spastic* line C57BL/6J *Glr*b^{spa/spa}. Although minigenes constructed on a C57BL/6J genetic background exhibited robust exon skipping, either in the presence of LINE1 sequences or specific splicing regulatory proteins, this missplicing was not observed in minigenes prepared from genomic DNA of C3H/HeJ mice. A polymorphic short nucleotide polymorphism (SNP) localized in *Glr*b exon 6 was found to function as an exonic splicing enhancer and thus regulating exon skipping by influencing binding of the essential splicing regulatory protein SRSF1 (formerly also known as ASF/SF2). These observations suggest that the missplicing observed in *Glr*b^{spa} mice results from a splicing signal mutation amplified by insertion of a LINE1 retrotransposon.

EXPERIMENTAL PROCEDURES

Generation of Minigene Constructs—Exon nomenclature was based on ensembl release 55 (18). Mouse *Glr*b (NM_010298) exon 4, 5' intron 4 (up to IVS4272), 3' intron 4 (from IVS4 + 15720), exon 5, intron 5, exon 6, intron 6 and exon 7 were amplified from C57BL/6J *Glr*b^{+/+}, C3H/HeJ *Glr*b^{+/+}, or C57BL/6J *Glr*b^{spa/spa} genomic DNA using long range PCR (Triple Master, Eppendorf, Germany). For *in vivo* splicing assays, inserts were cloned into the eukaryotic expression vector pRK7, which contains a CMV promoter, creating the minigenes B-WT (from C57BL/6J *Glr*b^{+/+} genomic DNA), C-WT (from C3H/HeJ *Glr*b^{+/+} genomic DNA), or Spa (from C57BL/6J *Glr*b^{spa/spa} genomic DNA). For analyzing protein expression, ORFs were created by adding to the respective Spa and B-WT minigenes cDNA sequences derived from the exons 1–3, including a sequence encoding for an N-terminal Myc tag as well as cDNA sequences encoding the sequences from exons 8 and 9, yielding a Spa plasmid of 15.84 kb. For comparable transfection conditions, the B-WT (7.02 kb) minigene was extended to a similar size (15.38 kb) by adding 6.8 kb of IVS4. The inclusion of this additional sequence did not affect splicing efficiencies (data not shown).

In Vivo Splicing Assays—HEK293 cells were grown in MEM supplemented with 10% (v/v) fetal calf serum and penicillin/streptomycin. Cells were plated at 2×10^5 cells/6 well and grown until 60% confluency. Transient transfection was carried out using calcium phosphate precipitation employing a total of 6 μ g of plasmid DNA/well. Minigenes were transfected at 2

μ g/well and splicing factors at increasing concentrations (up to 4 μ g). With total plasmid DNA <6 μ g/well, pEGFP-N1 (Clontech, Mountain View, CA) was co-transfected for filling in. *In vivo* splicing assays were performed as described (19). For protein expression analysis, HEK293 cells were transfected with the indicated constructs, and membrane preparations were performed as described previously (20). For RT-PCR analysis, RNA was isolated from transfected cells using standard GTC/phenol extraction method (PEQGold-RNA Pure, PEQLab, Erlangen, Germany). Total RNA (1–2 μ g) was reverse transcribed using a vector specific primer (pRK-Cis: 5'-AACCAT-TATAAGCTGCAATAAAC-3') and M-MuLV reverse transcriptase (New England Biolabs). 1–3 μ l of cDNA were used for PCR (GoTaq, Promega, Madison, WI; primers: E4 + 246-F, 5'-GTAGTCAACATTTTTTATTAATAG-3'; E7 + 656-R, 5'-AGGATCTCCTGACTGCCAGATGAA-3').

Western Blot Analysis—Western blot analysis was performed as described (20). The following antibodies were used: monoclonal anti-SRSF1 (32-4500, Invitrogen), monoclonal anti-GFP (Roche Applied Science); polyclonal anti-ATPA1 (sc-28801, Santa Cruz Biotechnology, Santa Cruz, CA), monoclonal anti-c-Myc (9E10; Santa Cruz Biotechnology); HRP conjugated goat anti-mouse F(ab)₂ fragments (Dianova, Hamburg, Germany).

In Vitro Transcription and Affinity Purification of *Glr*b Exon 6 RNA Binding Proteins—Procedures were performed as described previously (21). In brief, to generate an RNA probe of a *Glr*b exon 6 fragment (E6.13–E6.61), the corresponding linearized pBluescript II KS plasmid was transcribed *in vitro*. One nanomole (~7.9 μ g) of RNA was placed in a reaction mixture containing fresh 0.1 M NaOAc, pH 5.0, and 5 mM sodium *m*-periodate (Sigma). The reaction mixture was incubated for 1 h in the dark at room temperature. The RNA was ethanol-precipitated and resuspended. Then, prewashed adipic acid dehydrazide-agarose bead 50% slurry (Sigma) was mixed with the periodate-treated RNA sample and incubated for 12 h at 4 °C on a rotator. The RNA-bound beads were washed with RNA washing buffer. They were incubated in 1 \times RNA binding buffer with 0.3 mg of HeLa cell nuclear extract (CilBiotech) for 20 min at 30 °C, pelleted by centrifugation, and washed five times in RNA washing buffer. After the final centrifugation, 60 μ l of SDS-PAGE sample buffer were added to the beads and heated to 90 °C before loading onto a 10% SDS-PAGE gel, transferred to PVDF membranes, and probed with a monoclonal antibody directed against an N-terminal epitope of SRSF1 (Invitrogen).

siRNA Knockdown—The siRNA knockdown of SRSF1 in HEK293 cells was performed using the reverse transfection procedure according to the manufacturer's instructions (Qiagen, Hilden, Germany) on six-well plates. A sequence within the human SRSF1 coding region was selected for designing a siRNA (Dharmacon, Chicago, IL). Transfections with scrambled siRNAs were used as a control (sc-37007; Santa Cruz Biotechnology). After 48 h, 1000 ng/well of the Spa minigene was transfected as described earlier. RNA was isolated after 72 h of siRNA treatment (16–18 h after minigene transfection).

RESULTS

In the mutant mouse *spastic*, exon skipping from *Glr*b transcripts has been associated with an intronic insertion of a full-




FIGURE 1. *A*, structure of the *Glr*b gene surrounding the LINE1 insertion site. Exons are indicated as *gray boxes*, position as well as orientation of the LINE1 insertion is indicated by the *arrow*. Splicing of the pre-mRNA derived from the wild-type *Glr*b allele is indicated as *solid line*, splicing events observed in *Glr*b^{Spa} mice resulting in skipping of exon 6 ($\Delta 6$) as a *dashed line* or exons 5 and 6 ($\Delta 5/6$) as a *dotted line*, respectively. *B*, structure of the *Glr*b minigenes. Exons are depicted as *gray boxes*, and LINE1 is represented as an *open box*. The Spa minigene was generated from genomic DNA of a C57BL/6J *spastic* mouse (*Glr*b^{Spa/Spa}). The wild-type minigenes B-WT and C-WT were generated from genomic DNA of C57BL/6J and C3H/HeJ mice, respectively. *C*, RT-PCR analysis of HEK293 cells transfected with the minigenes indicated in *B* or spinal cord mRNA preparations from mice with the indicated genomic background and genotype. For amplification, primers specific for a *Glr*b amplicon containing the exons 4–7 were used. Expected sizes for the full-length amplicon, the $\Delta 6$ amplicon and the $\Delta 5-6$ amplicon are indicated. Note that skipping of exon 6 or the exons 5 and 6 was only observed in samples from Spa minigene expressing cells or *Glr*b^{Spa/Spa} mice. *D*, RT-PCR analysis from RNA preparations of N2A (mouse neuroblastoma cells, differentiated after 12 h of serum withdrawal), C2C12 (a mouse myoblast cell line, undifferentiated), HeLa cells and primary astrocytes derived from P0 C57BL/6J *Glr*b^{+/+} animals after transfection with the indicated minigenes. In all cell lines investigated, skipping of exon 6 could be observed reliably after transfection of the Spa minigene, whereas the combined skipping of exons 5 and 6 was highly variable.

length LINE1 element into intron 6 of the *Glr*b gene (Fig. 1*A*, see also Refs. 5 and 6). To study *Glr*b^{Spa} pre-mRNA missplicing, *in vivo* splicing assays were performed (19), using minigene constructs derived from genomic DNA from C57BL/6J *Glr*b^{Spa/Spa} (Spa), C57BL/6J *Glr*b^{+/+} (B-WT), and C3H/HeJ *Glr*b^{+/+} (C-WT) mice. Plasmids encompassing *Glr*b exons 4 to 7 (Fig. 1*B*) were transiently transfected into HEK293 cells, and RNA transcripts were analyzed by semiquantitative RT-PCR using primers binding in the exons 4 and 7, respectively. For both wild-type minigene constructs, *i.e.* B-WT and C-WT, only one amplicon was obtained which corresponded to the full-length transcript composed of exons 4–7 (Fig. 1*C*, lanes 1 and 2), consistent with the *Glr*b transcripts observed in cDNA preparations from spinal cord tissue of wild-type mice (Fig. 1*C*, lanes 4 and 5). In samples derived from cells transfected with the Spa minigene, additional shorter amplicons, corresponding to RNAs lacking either exon 6 ($\Delta 6$) or both, exons 5 and 6 ($\Delta 5/6$), (Fig. 1*C*, lane 3) were detected. Amplicons of identical size were observed in samples derived from spinal cord tissue of mutant mice carrying the *Glr*b^{Spa} allele (Fig. 1*C*, lane 6, see also Ref. 6).

Interestingly, although skipping of exon 6 was reliably detected in samples from transfected HEK293 cells only a faint band representing the amplicon from a $\Delta 5/6$ mRNA was visible. Testing of other cell lines including neuroblastoma cells as well as primary mouse astrocytes revealed that the combined skipping of exons 5/6 was highly variable between experiments and in addition depended on the cell type used for analysis (Fig. 1*D*). Therefore, we focused on missplicing of exon 6, which was reliably detected in all cell types tested.

LINE1-associated Glrb Missplicing Depends on Genetic Context—To determine whether a full-length LINE1 insertion is necessary to induce missplicing, we performed deletion analysis of the LINE1 sequence. When most of the LINE1 sequence was missing, exon skipping was nearly absent (Fig. 2*A*, lanes 3 and 4), whereas deletion of a fragment from ORF2 alone did not prevent missplicing (Fig. 2*A*, lane 2). To test which LINE1 segments were necessary for missplicing, five overlapping fragments (Fig. 2*B*, *F1–F5*) were cloned individually into both wild-type minigenes (B-WT and C-WT) at position IVS6 + 193, matching the site of LINE1 integration into intron 6 of the

Molecular Analysis of *Glr*b Missplicing in *Glr*b^{Spa} Mice




FIGURE 2. LINE1 associated exon skipping depended on the genetic context. *A*, deletion constructs containing only fragments of the LINE1 element were generated from the Spa minigene by internal restriction digest. ORFs within the LINE1 are indicated as *gray boxes*. After transfection in HEK293 cells and RNA extraction from the transfected cells, RT-PCR analysis was performed. Deletion of 2.3 kb from ORF2 did not change splicing, whereas exon skipping was diminished with larger deletions ($\Delta 6456$ bp, $\Delta 7137$ bp; *lanes 3 and 4*). *B*, minigenes containing the indicated LINE1 fragments F1 to F5 at the position of the original LINE1 insertion were generated on the basis of genomic DNA from C57BL/6J and C3H/HeJ mice. The respective minigenes were transfected in HEK293 cells and mRNA extracts analyzed by RT-PCR analysis. Of note, only the 3' UTR plus 370 bps of ORF2 and 5' UTR, respectively, promoted exon skipping when inserted into *Glr*b minigenes derived from C57BL/6J. *C*, schematic drawing of the construction of a chimeric C3H/HeJ Spa minigene containing exons 4–6 based on the C3H/HeJ genomic DNA and the fragment F5–E7 sequence containing the region IVS6 + 194–exon 7 from the Spa construct. After transfection in HEK293 cells and RNA extraction from the transfected cells, RT-PCR analysis was performed. *D*, schematic drawing of the construction of a Spa C3H/HeJ minigene. A fragment containing E4–IVS5 + 193 from C3H/HeJ genetic background was introduced in the Spa minigene, replacing the homologous region within the Spa minigene suppresses exon skipping despite the presence of a full-length LINE1. For analysis, HEK293 cells were transfected with the indicated minigenes, and exon skipping was determined by RT-PCR.

*Glr*b^{Spa} allele. Exon skipping similar to the Spa minigene was only observed for constructs B-F1 and B-F5, encompassing the 3' UTR and adjacent 370 bp of ORF2, or the 5' UTR of the LINE1, respectively (Fig. 2*B*, *lanes 3 and 5*). Surprisingly, aberrant splicing was completely absent in similar minigenes generated from genomic DNA of C3H/HeJ mice (Fig. 2*B*, *lanes 2 and 4*). Apparently, *Glr*b missplicing was suppressed in the C3H/HeJ genomic context. To evaluate which parts of the C-WT sequence were necessary for suppression of exon 6 skipping, the F5 fragment of the LINE1 sequence and adjoining *Glr*b sequences, including exon 7, were excised from the Spa minigene (Fig. 2*C*) and cloned into C-WT downstream of the *Agel* site, thereby generating the hybrid C-(F5-E7)^{Spa} minigene (Fig. 2*C*). Exon skipping was also absent in cells transfected with this minigene, indicating that the upstream exons 4–6 from C-WT were sufficient for suppression of missplicing. Moreover, swapping of exons 4–6 from the C-WT minigene with Spa, yielding the construct Spa-(E4-6)^{C-WT}, prevented aberrant splicing (Fig. 2*D*, *lane 3*), although this minigene contained

the full-length LINE1. Similarly, no missplicing was observed with the C-(E4-6)^{Spa} minigene (Fig. 2*D*, *lane 2*). Taken together, these results suggest that in addition to the insertion of the LINE1 element, a second sequence element present in the fragment containing the exons 4–6 is required for the missplicing observed in *Glr*b^{Spa} mice.

Using RNA regulatory motif prediction (22–24), we searched for sites within *Glr*b exons 4–6 able to modulate exon inclusion, *e.g.* by providing binding sites for splicing regulatory factors such as serine/arginine-rich (SR) or heterogeneous ribonucleoproteins. In particular, we focused on sequence elements that were polymorphic between C57BL/6J and C3H/HeJ. A single nucleotide polymorphism (*Glr*b^{rs13477223}) was found to coincide with an exonic splicing enhancer (ESE) motif in exon 6, predicted to bind the SR protein SRSF1 (Fig. 3*A*, *boxed*; Table 1). Here, an A allele is present at position E6.28 in C57BL/6J (E6.28A, B-type), whereas a G allele is found in C3H/HeJ (E6.28G, C-type). Based on our motif prediction, the G-allele present in the C-WT minigene contributes to an SRSF1 binding




FIGURE 3. LINE1-associated skipping of exon 6 depended on a polymorphic residue at position E6.28. *A*, sequence of the *Glrb* exon 6 from C57BL/6J and C3H/HeJ mice, including the surrounding intronic regions. Exonic sequence is displayed in *uppercase letters*. Sequence motifs predicted to bind to SRSF1 are indicated. Note that one SRSF1 site predicted E6.23 in the C3H/HeJ exon 6 was not detected in the C57BL/6J due to a SNP at position E6.28 (A, strain C57BL/6J; G, strain C3H/HeJ; *dbSNP*, rs13477223). *B*, the effect of the SNP at position E6.28 was analyzed by introducing a G at E6.28 in the Spa minigene. The indicated minigenes were transfected into HEK293 cells and exon skipping was analyzed by RT-PCR. Note that mutation of E6.28 in the Spa minigene to a G (Spa-E6.28G) was sufficient to prevent skipping of exon 6. *C*, B-WT, Spa, and Spa E6.28G minigenes were complemented to full-length ORFs by adding coding sequences of the *Glrb* exons 1–3, including an N-terminal Myc tag and at the 5' end and coding sequences of the exons 8–9 at the 3' end of the minigene. The constructs were transfected into HEK293 cells and exon skipping was analyzed by RT-PCR using primers positioned in exons 4 and 9. *D*, membrane preparations from HEK293 cells transfected with the minigenes containing the full-length GlyR β ORF as indicated and for testing transfection efficiencies a plasmid encoding for GFP, were subjected to SDS-PAGE and Western blot analysis. The blots were probed with antibodies against Myc, ATPA1, and GFP. *E*, expression levels from the experiment shown in *D* as quantified by scanning of the blots and densitometric analysis using NIH ImageJ software. Note that in contrast to samples from WT and Spa-E6.28G transfected cells, samples from Spa transfected cells, showed almost no Myc immunoreactivity although the cells were transfected efficiently as indicated by GFP immunoreactivity.

TABLE 1

Prediction of splicing factor binding at rs13477223

Default thresholds were used for all web-based prediction tools. For ESE finder and Altsplice, only factors predicted to bind at E6.28 are listed with scores obtained for E6.28 A versus E6.28G.

Modification	ESE finder	Altsplice	Rescue ESE	Observation
E6.28 A>G (c.555A>G; rs13477223)	SRSF1, n.d./2.41 SRSF2, 4.59/5.04 SRSF5, 4.10/4.67	SRSF1 (10-mer), 5.13/5.93 SRSF1 (7-mer), n.d./3.05 SRSF5 (5-mer), n.d./3.24 SRSF2 (8-mer), 4.70/5.13	None found at position None found at position	A, exon 6 skipped G, no skipping

site that was absent in Spa (B-type). A second SRSF1 binding motif was predicted 23 bp downstream of this site, which was identical in both C57BL/6J and C3H/HeJ (Fig. 3A, *underlined*). To test whether differences in splicing could be attributed to the polymorphism rs13477223, residues at position E6.28 were swapped, thereby generating the minigenes C-E6.28A and Spa-E6.28G. Upon expression, skipping of exon 6 could be observed only with the original Spa construct, containing the B-type nucleotide E6.28A (Fig. 3B, *lane 3*). In contrast, a G-residue at this position (C-type) was sufficient to prevent skipping of exon 6 despite the presence of a full-length LINE1 (Fig. 3B, *lane 4*). Similarly, no missplicing was observed in cells transfected with the C-E6.28A minigene (data not shown). These findings suggest that the polymorphism at position E6.28 significantly contributes to the missplicing observed in Spa mice. To test whether this modulation of exon skipping by nucleotide E6.28 was also evident at the level of the full-length GlyR β subunit protein, we created translatable ORFs from both Spa and Spa-

E6.28G minigenes by adding cDNA sequences containing the sequences encoded by the exons 1–3 at the 5' end, as well as exons 8–9 at the 3' end of both Spa constructs. For detection, a sequence encoding for an N-terminal Myc tag was incorporated. Whereas the B-WT and Spa E6.28G minigenes produced only full-length mRNA (data not shown and Fig. 3C), robust skipping of exon 6 was observed in minigenes derived from the Spa sequence (Fig. 3C, *left panel*). Western blot analysis of detergent extracts from B-WT transfected cells revealed a doublet of Myc immunoreactive bands of ~60 kDa that might result from different glycosylation forms of the full-length GlyR β protein in this cell system. Consistent with our cDNA data similar immunoreactive signals were observed in samples from cells transfected with the Spa E6.28G minigenes (Fig. 3D) but not in samples from Spa minigene expressing cells.

Modulation of Exon Skipping by the Splicing Factor SRSF1—The ESE polymorphism between B-WT and C-WT resides within a putative binding site for splicing factor SRSF1. We




FIGURE 4. **Modulation of exon skipping by splicing factor SRSF1.** *A*, pull-down assays of HeLa nuclear extracts were conducted using *in vitro*-transcribed *Glr*b E6.13–E6.61 RNA containing either E6.28G (C-WT) or E6.28A (Spa). After pull-down, proteins were analyzed by Western blotting using a monoclonal antibody against SRSF1. Using a C-WT derived sequence, a strong signal for SRSF1 was detected at 33 kDa, which was diminished when a E6.28G RNA fragment was used as a bait. *Lower panel*, for quantification band intensities were analyzed using ImageJ software. All values represent means \pm S.E. ($n = 3$). **, $p < 0.01$ (one-way ANOVA followed by Bonferroni's multiple comparison test). *B*, HEK293 cells were cotransfected with an expression construct for SRSF1 and the minigenes as indicated. In RNA preparations from these cells, exon skipping was analyzed by RT-PCR using primers positioned in exons 4 and 7. *C*, HEK293 cells were transfected with 200 or 400 ng of an SRSF1 specific siRNA or 400 ng of scrambled siRNA. Efficiency of SRSF1 knockdown was determined in Western blot from protein extracts of transfected cells using an SRSF1-specific antibody. Comparable loading of the gel was assessed by probing the Western blot with antibodies against GAPDH (*D*); HEK293 cells were transfected with siRNA as described in *C*. After 24 h, cells were transfected additionally with the Spa minigene. Exon skipping was analyzed in RNA preparations from these cells using primers positioned in exons 4 and 7. For quantification, band intensities were determined on digital images of the gel using ImageJ software. All values represent means \pm S.E. ($n = 3$). **, $p < 0.01$ (one-way ANOVA followed by Bonferroni's multiple comparison test).

assayed SRSF1 binding to *Glr*b exon 6 RNA using fragments from Spa and C-WT encompassing the polymorphic E6.28 and using them for pull-downs from HeLa nuclear extracts to biochemically test for a possible reduction of binding to E6.28A containing sequences. In pull-downs using C-WT RNA fragments as bait, strong SRSF1 binding was observed. On the other hand, in samples where a Spa RNA fragment was used as a bait, binding of SRSF1 was significantly reduced (Fig. 4A), consistent with the predicted loss of SRSF1 binding motif in Spa RNA. Upon overexpression of SRSF1, enhanced skipping of exon 6 was observed in RNA preparations from cells transfected with minigenes lacking the second SRSF1 binding site (E6.28A, constructs B-WT and Spa, Fig. 4B, lanes 2 and 3; compare with Fig. 3). Conversely, no skipping of exon 6 was detected in C-WT and Spa E6.28G (Fig. 4B, lanes 1 and 4). The effect of reduced SRSF1 levels on exon skipping was then analyzed by a siRNA-based approach. Here, transfection of HEK293 cells with a SRSF1-specific siRNA resulted in an efficient reduction of SRSF1 expression, whereas SRSF1 levels in cells transfected with control siRNA was comparable with untransfected cells (Fig. 4C and data not shown). Upon co-transfection of siRNAs and the Spa minigene, robust skipping of exon 6 was observed in cells transfected with control siRNA, whereas co-transfection of SRSF1 specific siRNA resulted in enhanced inclusion of exon 6

in a dose-dependent manner (Fig. 4D), suggesting that SRSF1 is an important splicing regulator for this exon. Taken together, these data suggest that the LINE1 sequences modifies splicing by binding and/or sequestering SR proteins, in particular SRSF1, in a sequence and/or position dependent manner. The possibility that transcription from an internal LINE1 promoter interfered with *Glr*b splicing was excluded, since no LINE1 specific amplicons were detected in samples from cells transfected with the Spa minigenes (data not shown).

To determine a minimal sequence of the LINE1 sufficient to induce exon skipping in an E6.28A environment, we performed deletion analysis of constructs B-F1 (3' UTR and adjacent 370 bp of ORF2) and B-F5 (5' UTR) to obtain fragments amenable to mutational studies (Fig. 5, data not shown). As F1 is located closest to exon 6 in Spa, we conducted a detailed analysis of this fragment. Truncations from its 5' and 3' ends were obtained by PCR (Fig. 5A). Skipping of exon 6 and/or exons 5/6 was still observed, albeit weakly, in minigenes lacking the utmost 3' sequences of the LINE1, indicating that the 303 bp at the 5' end of F1 were the smallest LINE1-derived sequence sufficient to induce exon skipping (Fig. 5A, lanes 4–6). Smaller deletions of the minigene construct 5'-303 did not induce overt exon skipping (data not shown). As it is known that the direction of LINE1 insertion contributes to the severity of the LINE1-in-




FIGURE 5. Delineating the LINE1 minimal sequence required to induce exon skipping. *A*, truncations of F1 (corresponding to the 3' UTR and adjacent 370 bp of ORF2) from either its 5' end (constructs F1 3'-820, 3'-529, 3'-219) or its 3' end (F1 5'-303, 5'-594, 5'-904) were generated by PCR and inserted into C-6.28A via *AgeI* (schematic in *left panel*). The respective constructs were transfected in HEK293 cells. RNA extracts from these cells were analyzed by RT-PCR using primers binding in exons 4 and 7, respectively. Skipping was more apparent in minigenes containing LINE1 3' deletions (*right panel, lanes 4–6*) and when inserts were oriented in sense with respect to *Glr*b sequences (*right panel, lanes 10–12*). *B*, mutations (m1–m4) in fragment F1–5'–303 of predicted SRSF1 binding sites were introduced to reduce SRSF1 binding to the fragment. Putative SRSF1 binding sites are underscored, mutated residues in *boldface type*. *Left panel*, statistical analysis comparing 5'–303 and 5'–303m1–4. All values represent means \pm S.E. ($n = 3$). Note that the combined mutations m1–4 resulted in a significant reduction of exon skipping (*lanes 1–5*). **, $p > 0.001$, one-way ANOVA followed by Bonferroni's multiple comparison test. *C*, skipping of exon 6 depends on the distance of the LINE1 insertion to the skipped exon. *Upper panel*, plasmid constructs were derived from the C-E6.28A minigene. A fragment of the LINE1 corresponding to its 5' UTR (F5) was inserted at intronic positions IVS6 + 528, +870, +1154 into the C-E6.28A minigene via an *AgeI* site. The full-length LINE1 sequence was inserted into "skipping-permissive" B-WT introns 4 (IVS4.15513) and 7 (IVS7.873); this minigene also contains an exon 8 and adjacent intronic sequence IVS7–3720–4223) via a *PmlI* and *Sall* site, respectively. *Lower panel*, exon 6 skipping was significantly reduced with increasing distance from the exon (*lanes 1–3, graph*); for comparison, see Spa (*lane 4*). No skipping of exon 6 could be observed with insertions in introns 4 and 7 (*lanes 5 and 6*). Restoring the weak 5' splice donor site (5' ss) of intron 6 to consensus (replacing ..GCTgtatgt.. with ..CAGgtaagt...) in the Spa construct prevented skipping despite the presence of the full-length LINE1 insertion (*lane 7*). All values represent means \pm S.E. ($n = 3$). *, $p < 0.05$ (one-way ANOVA followed by Bonferroni's multiple comparison test).

duced effects on mRNA levels (11, 20), we tested corresponding minigenes with sense inserts (with respect to *Glr*b), three of which exhibited pronounced skipping (Fig. 5A, lanes 10–12).

To evaluate the hypothesis that sequestration of SRSF1 by the short LINE1 fragment would enhance skipping, SRSF1 binding motif prediction was performed using the 5'–303-bp

Molecular Analysis of *Glr*b Missplicing in *Glr*b^{Spa} Mice

TABLE 2

Prediction of SRSF1 binding in LINE1 fragment 303

Default thresholds were used for all web-based prediction tools. Binding sites mutated are indicated in boldface type. Predictions derived for the mutated sites are indicated after the slash. Mut, mutation.

Position (start) sense	ESE finder (7-mer) 5'-303/5'-303 Mut	Altsplice (7-mer) 5'-303/5'-303 Mut	Rescue ESE (6-mer) 5'-303/5'-303 Mut
2	2.411/2.411	3.057/3.057	4/4
16	4.493 /n.d.	4.664 /n.d. (12:2.717)	
26	2.284 /n.d.	2.745/n.d.	27, 6/34, 2
40		2.240/2.240	
48	2.040/n.d.		
51	5.291 /n.d.	5.390 /n.d.	3/56, 1
87	3.819/3.819	4.152/4.152	8/8
113	2.080 /n.d.		107 , 3/107, 2
138	2.876/2.876	3.083/3.083	1/1
156			12/8
175			2/3
189	5.738/n.d.	6.058 /n.d.	187 , 12/194, 8
215			3/3
248			5/5
265			1/1
279			3/3
291			1/1

fragment oriented in antisense (Spa) or sense with respect to *Glr*b, and sequences were mutated to abolish predicted binding sites (Table 2). Although neither single nor combined mutations of the fragment oriented in Spa direction diminished skipping further (data not shown), combined mutations in sense orientation lead to a significant increase in exon 6 inclusion, suggesting that interaction of SRSF1 with the LINE1-derived sequence is important for splicing modulation (Fig. 5B, lanes 2–5). In known examples of SR protein-mediated inhibition of exon inclusion, an interaction of the respective factors bound to intronic regulatory elements and the essential snRNPs attached at the 5' and 3' splice sites has been postulated (21, 25). To disrupt these putative short range interaction, we moved the F5 sequence of the LINE1, which has been shown to be sufficient for the induction of exon skipping downstream of its insertion site at IVS6.193 (F5 in Fig. 5C). This resulted in a diminished skipping of exon 6 with increasing distance from the exon (for quantification, see lower right panel of Fig. 5C). Similarly, the moving of the entire LINE1 into introns 4 or 7, respectively in a B-WT background, did not result in missplicing, suggesting that the proximity of the LINE1 insertion to the skipped exon is important. Furthermore, computational prediction revealed a weak 5' splice donor site (5' ss) of *Glr*b intron 6 (score < 0.15; NNSPLICE (26)), enabling SR proteins bound to a downstream intronic site to compete for binding of the essential small nuclear RNA protein U1. Accordingly, mutating the *Glr*b donor site to a perfect splicing consensus sequence abolished E6 skipping in the presence of a full-length LINE1 (Fig. 5C, lane 7). Thus, the *Glr*b^{Spa} allele is characterized by an intronic antisense LINE1 insertion, which amplifies the impairment of pre-mRNA splicing in a weak neighboring exon.

DISCUSSION

In this study, we analyzed the molecular details resulting in LINE1-induced missplicing in the *Glr*b mutant mouse *spastic*, using a minigene approach. Comparison of splicing products obtained from the respective WT minigenes and with minigenes engineered from the Spa gene revealed differences in splicing similar to those found *in vivo*. We could show that skipping of exon 6 as seen in RNA preparations from spinal cords of Spa

mice was reliably detectable in cells transfected with the Spa minigene, thus allowing a detailed analysis of the mechanisms leading to this missplicing phenotype. Interestingly, the combined skipping of exon 5 and 6 as seen in samples from *Glr*b^{Spa} mice was highly variable between cell types or preparations and thus precluded further analysis. Using truncations of the inserted LINE1 as well as reconstruction of a Spa minigene on a C3H/HeJ background, we demonstrated that the splicing defect of *Glr*b pre-mRNA in Spa mice results from the interaction of a SNP affecting an ESE site with the adjacent intronic LINE1. In our assay system, the substitution of a single nucleotide restored normal wild-type splicing at the level of mRNA and allowed for the transcription of full-length protein, despite the presence of the full-length LINE1 insertion. The fact that the substitution of a single nucleotide was sufficient to significantly alter the LINE1 associated missplicing points to the importance of SNPs in the context of gene regulation. *Glr*b SNP rs13477223 belongs to the class of coding polymorphisms that do not alter protein sequence or splicing of the wild-type *Glr*b pre-mRNA. Our findings indicate, however, that the SNP can modulate pre-mRNA splicing and thereby alters the physiological function of the encoded protein when placed in a different genetic environment. As retrotransposition events are thought to be rare (one LINE1 insertion per 212 births (11, 27)) and point mutations occur at a much higher frequency (28), tissue-specific genetic variation might result from the interaction of intronic DNA repetitive elements or fragments thereof and an individual set of exonic SNPs within defined regulatory sequences. The strength of the splicing regulatory sequences, in our case an ESE localized within exon 6, then becomes critical to determine whether the adjacent retroelement becomes apparent phenotypically.

We have previously shown that the intronic insertion of an antisense LINE1 into *Glr*b intron 6 is associated with exon skipping (6). The exact mechanism, however, by which LINE1 insertions induce exon skipping had not yet been fully characterized. An overall decrease of mRNA levels due to LINE sequences has been observed for exonic and splice site insertions (12, 29). Although the disruption of consensus splice sites

at the exon-intron border and of exonic splicing regulatory sites can account for missplicing events and the consecutive decrease in full-length transcripts, intronic insertions also result in a reduction of mature mRNA. The occurrence of length-dependent elongation defects (17) and premature polyadenylation (30) were found causative in experimental minigene systems and *in vivo*. The *Glr*b^{Spa} allele, however, is associated with exon skipping, but no LINE1-*Glr*b chimeric transcripts indicative of LINE1 cryptic splice site usage were detected in affected animals by Northern blot analysis (6).⁴ Moreover, by using *in vivo* splicing assays and analysis of full-length protein, we found comparable levels of correctly spliced cDNA and of full-length protein for both, Spa E6.28G with a LINE1 antisense insertion and WT minigenes. These findings suggest that LINE1 DNA is transcribed completely and subsequently spliced out. In the *Glr*b^{Spa} allele, distinct sequence fragments of the LINE1 appear to act analogous to intronic splicing silencers and a number of intronic silencer elements are known to promote exon skipping in the presence of SR proteins (21). In the *Glr*b^{Spa} allele, inclusion of exon 6 is hampered by a weak splice donor site and, in the C57BL/6J genomic background, a missing ESE. When the respective sites were improved by either substituting a residue at position 5 of the heptameric ESE predicted to bind SRSF1 (22, 31) or by restoring the 5' splice donor site of *Glr*b intron 6 to consensus renders the adjacent LINE1 ineffective.

Our findings suggest that in *Glr*b^{Spa}, the LINE1 is interfering with the splicing machinery. We excluded the possibility that the LINE1 is transcribed from an internal antisense promoter. Furthermore, only defined segments of the LINE1 were associated with exon skipping: its 5' and 3' UTR and smaller fragments thereof, which were unlikely to function as promoter elements in this system. One possibility, by which an LINE1 element could interfere with pre-mRNA splicing, is the binding and sequestration of SR molecules and the interaction with defined regulatory proteins bound to adjacent exons, as in our study SRSF1. Because such interactions are limited with respect to distance, the impact of intronic LINE1 insertions most likely depends on the proximity to exons. Consistently, increasing the distance of the LINE1 to exon 6 ameliorated the skipping of the exon in our minigene assays. Moreover, not all exons in the vicinity appear to be affected similarly, as we have demonstrated by moving the full-length LINE1 to neighboring introns. The observation that the degree of exon skipping seen in *in vivo* minigene assays also depended on the cell type and diverged partially from the splicing seen in spinal cord tissue suggest that the effect of the LINE1 insertion is a combination of cis- and trans-acting factors that can thus be attenuated by cellular factors such as splicing regulatory proteins, even when sequence determinants are unfavorable, as in C57BL/6J *Glr*b^{Spa}.

In summary, we have shown that missplicing of the murine glycine receptor β subunit observed in the mutant mouse *spastic* is the result of a two-hit mutation consisting of a hypomorphic SNP that leads to the destruction of an ESE within exon 6 becoming functionally amplified by the insertion of a LINE1 in

the adjacent intron of the Spa allele. Further aggravation comes from a weak splice donor site delineating the exon upstream of the LINE1 insertion site. Taken together, our findings provide insights in the molecular mechanisms of the LINE-induced changes in splicing observed in the mutant mouse *spastic*.

Acknowledgments—We thank Marina Wenzel, Annette Serwotka, and Rosa Weber for expert technical assistance and Drs. Katrin Schiebel and Pamela Strissel for a critical reading of the manuscript.

REFERENCES

1. Betz, H., and Laube, B. (2006) Glycine receptors: Recent insights into their structural organization and functional diversity. *J. Neurochem.* **97**, 1600–1610
2. Grudzinska, J., Schemm, R., Haeger, S., Nicke, A., Schmalzing, G., Betz, H., and Laube, B. (2005) The β subunit determines the ligand binding properties of synaptic glycine receptors. *Neuron* **45**, 727–739
3. Oertel, J., Villmann, C., Kettenmann, H., Kirchhoff, F., and Becker, C. M. (2007) A novel glycine receptor β subunit splice variant predicts an unorthodox transmembrane topology. Assembly into heteromeric receptor complexes. *J. Biol. Chem.* **282**, 2798–2807
4. Harvey, R. J., Topf, M., Harvey, K., and Rees, M. I. (2008) The genetics of hyperekplexia: More than startle! *Trends Genet.* **24**, 439–447
5. Kingsmore, S. F., Giros, B., Suh, D., Bieniarz, M., Caron, M. G., and Seldin, M. F. (1994) Glycine receptor β -subunit gene mutation in spastic mouse associated with LINE-1 element insertion. *Nat. Genet.* **7**, 136–141
6. Mülhardt, C., Fischer, M., Gass, P., Simon-Chazottes, D., Guénet, J. L., Kuhse, J., Betz, H., and Becker, C. M. (1994) The spastic mouse: Aberrant splicing of glycine receptor β subunit mRNA caused by intronic insertion of L1 element. *Neuron* **13**, 1003–1015
7. Becker, C. M., Hermans-Borgmeyer, I., Schmitt, B., and Betz, H. (1986) The glycine receptor deficiency of the mutant mouse spastic: Evidence for normal glycine receptor structure and localization. *J. Neurosci.* **6**, 1358–1364
8. Babushok, D. V., Ostertag, E. M., and Kazazian, H. H., Jr. (2007) Current topics in genome evolution: Molecular mechanisms of new gene formation. *Cell Mol. Life Sci.* **64**, 542–554
9. Han, J. S., and Boeke, J. D. (2005) LINE-1 retrotransposons: Modulators of quantity and quality of mammalian gene expression? *Bioessays* **27**, 775–784
10. Brouha, B., Schustak, J., Badge, R. M., Lutz-Prigge, S., Farley, A. H., Moran, J. V., and Kazazian, H. H., Jr. (2003) Hot L1s account for the bulk of retrotransposition in the human population. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 5280–5285
11. Kazazian, H. H., Jr., and Moran, J. V. (1998) The impact of L1 retrotransposons on the human genome. *Nat. Genet.* **19**, 19–24
12. Chen, J., Rattner, A., and Nathans, J. (2006) Effects of L1 retrotransposon insertion on transcript processing, localization, and accumulation: Lessons from the retinal degeneration 7 mouse and implications for the genomic ecology of L1 elements. *Hum. Mol. Genet.* **15**, 2146–2156
13. Becker, K., Hohoff, C., Schmitt, B., Christen, H. J., Neubauer, B. A., Sandrieser, T., and Becker, C. M. (2006) Identification of the microdeletion breakpoint in a GLRA1 null allele of Turkish hyperekplexia patients. *Hum. Mutat.* **27**, 1061–1062
14. Burwinkel, B., and Kilimann, M. W. (1998) Unequal homologous recombination between LINE-1 elements as a mutational mechanism in human genetic disease. *J. Mol. Biol.* **277**, 513–517
15. Meischl, C., Boer, M., Ahlin, A., and Roos, D. (2000) A new exon created by intronic insertion of a rearranged LINE-1 element as the cause of chronic granulomatous disease. *Eur. J. Hum. Genet.* **8**, 697–703
16. Narita, N., Nishio, H., Kitoh, Y., Ishikawa, Y., Ishikawa, Y., Minami, R., Nakamura, H., and Matsuo, M. (1993) Insertion of a 5'-truncated L1 element into the 3' end of exon 44 of the dystrophin gene resulted in skipping of the exon during splicing in a case of Duchenne muscular dystrophy. *J. Clin. Invest.* **91**, 1862–1867

⁴ K. Becker, unpublished observations.

Molecular Analysis of *Glrb* Missplicing in *Glrb^{spa}* Mice

- Han, J. S., Szak, S. T., and Boeke, J. D. (2004) Transcriptional disruption by the L1 retrotransposon and implications for mammalian transcriptomes. *Nature* **429**, 268–274
- Hubbard, T. J., Aken, B. L., Ayling, S., Ballester, B., Beal, K., Bragin, E., Brent, S., Chen, Y., Clapham, P., Clarke, L., Coates, G., Fairley, S., Fitzgerald, S., Fernandez-Banet, J., Gordon, L., Graf, S., Haider, S., Hammond, M., Holland, R., Howe, K., Jenkinson, A., Johnson, N., Kahari, A., Keefe, D., Keenan, S., Kinsella, R., Kokocinski, F., Kulesha, E., Lawson, D., Longden, I., Megy, K., Meidl, P., Overduin, B., Parker, A., Pritchard, B., Rios, D., Schuster, M., Slater, G., Smedley, D., Spooner, W., Spudich, G., Trevanion, S., Vilella, A., Vogel, J., White, S., Wilder, S., Zadissa, A., Birney, E., Cunningham, F., Curwen, V., Durbin, R., Fernandez-Suarez, X. M., Herrero, J., Kasprzyk, A., Proctor, G., Smith, J., Searle, S., and Flicek, P. (2009) Ensembl 2009. *Nucleic Acids Res.* **37**, D690–697
- Stoss, O., Stoilov, P., Hartmann, A. M., Nayler, O., and Stamm, S. (1999) The *in vivo* minigene approach to analyze tissue-specific splicing. *Brain Res. Brain Res. Protoc.* **4**, 383–394
- Humeny, A., Bonk, T., Becker, K., Jafari-Boroujerdi, M., Stephani, U., Reuter, K., and Becker, C. M. (2002) A novel recessive hyperekplexia allele GLRA1 (S231R): Genotyping by MALDI-TOF mass spectrometry and functional characterization as a determinant of cellular glycine receptor trafficking. *Eur. J. Hum. Genet.* **10**, 188–196
- Buratti, E., Stuani, C., De Prato, G., and Baralle, F. E. (2007) SR protein-mediated inhibition of CFTR exon 9 inclusion: Molecular characterization of the intronic splicing silencer. *Nucleic Acids Res.* **35**, 4359–4368
- Cartegni, L., Wang, J., Zhu, Z., Zhang, M. Q., and Krainer, A. R. (2003) ESEfinder: A web resource to identify exonic splicing enhancers. *Nucleic Acids Res.* **31**, 3568–3571
- Houdayer, C., Dehainault, C., Mattler, C., Michaux, D., Caux-Moncoutier, V., Pagès-Berhouet, S., d'Enghien, C. D., Laugé, A., Castera, L., Gauthier-Villars, M., and Stoppa-Lyonnet, D. (2008) Evaluation of *in silico* splice tools for decision making in molecular diagnosis. *Hum. Mutat* **29**, 975–982
- Thanaraj, T. A., Stamm, S., Clark, F., Riethoven, J. J., Le Texier, V., and Muilu, J. (2004) ASD: The Alternative Splicing Database. *Nucleic Acids Res.* **32**, D64–69
- Cartegni, L., Chew, S. L., and Krainer, A. R. (2002) Listening to silence and understanding nonsense: Exonic mutations that affect splicing. *Nat. Rev. Genet.* **3**, 285–298
- Reese, M. G., Eeckman, F. H., Kulp, D., and Haussler, D. (1997) Improved splice site detection in Genie. *J. Comput. Biol.* **4**, 311–323
- Graham, T., and Boissinot, S. (2006) The genomic distribution of L1 elements: The role of insertion bias and natural selection. *J. Biomed. Biotechnol.* **2006**, 75327
- López-Bigas, N., Audit, B., Ouzounis, C., Parra, G., and Guigó, R. (2005) Are splicing mutations the most frequent cause of hereditary disease? *FEBS Lett.* **579**, 1900–1903
- Takahara, T., Ohsumi, T., Kuromitsu, J., Shibata, K., Sasaki, N., Okazaki, Y., Shibata, H., Sato, S., Yoshiki, A., Kusakabe, M., Muramatsu, M., Ueki, M., Okuda, K., and Hayashizaki, Y. (1996) Dysfunction of the Orleans reeler gene arising from exon skipping due to transposition of a full-length copy of an active L1 sequence into the skipped exon. *Hum. Mol. Genet.* **5**, 989–993
- Perepelitsa-Belancio, V., and Deininger, P. (2003) RNA truncation by premature polyadenylation attenuates human mobile element activity. *Nat. Genet.* **35**, 363–366
- Liu, H. X., Zhang, M., and Krainer, A. R. (1998) Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. *Genes Dev.* **12**, 1998–2012